Anti-infective Drugs Market

Executive Summary

Anti-infective Drugs Market was valued at US $248.56 billion in 2021 and is projected to grow at 12.98% CAGR over the forecast period to reach US $516.95 billion by 2027. Anti-infective Drugs Market represented US $53.83 billion opportunity over 2019-2021 and estimated to create US $268.39 billion opportunity in 2027 over 2021.

Anti-infective Drugs from Consainsights analyses the Anti-infective Drugs Market in the Life Sciences industry over the forecast period to 2027.

Anti-infective Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Anti-infective Drugs segmentation includes Product Type, Indication, Distribution Channel and Geography.

Based on the Product Type, the Anti-infective Drugs analysis covers Antibiotics, Antivirals, Antifungals, Other Products.

In Product Type segment, Antibiotics segment has highest cagr growth of 11.46%.

Based on the Indication, the Anti-infective Drugs analysis covers HIV Infection, Pneumonia, Respiratory Virus Infection, Sepsis, Tuberculosis, Other Indications.

In Indication segment, HIV Infection segment has highest cagr growth of 11.46%.

Based on the Distribution Channel, the Anti-infective Drugs analysis covers Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels.

In Distribution Channel segment, Hospital Pharmacy segment has highest cagr growth of 11.46%.

Based on the region, the Anti-infective Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Abbott Laboratories, Astellas Pharma Inc, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc, Sanofi SA and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, Antibiotics segment has the highest revenue of US $150.33 billion and is expected to grow at CAGR of 11.46% by 2027 Antibiotics segment has highest cagr growth of 11.46%.

Antibiotics

Antibiotics segment was valued at US $117.77 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $312.65 billion by 2027. Antibiotics segment represented US $32.56 billion opportunity over 2019-2021 and estimated to create US $162.32 billion opportunity in 2027 over 2021.

Antivirals

Antivirals segment was valued at US $48.32 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $128.29 billion by 2027. Antivirals segment represented US $13.36 billion opportunity over 2019-2021 and estimated to create US $66.61 billion opportunity in 2027 over 2021.

Antifungals

Antifungals segment was valued at US $25.38 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $67.39 billion by 2027. Antifungals segment represented US $7.02 billion opportunity over 2019-2021 and estimated to create US $34.99 billion opportunity in 2027 over 2021.

Other Products

Other Products segment was valued at US $3.25 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $8.62 billion by 2027. Other Products segment represented US $0.90 billion opportunity over 2019-2021 and estimated to create US $4.47 billion opportunity in 2027 over 2021.

Indication

Introduction

In 2021, HIV Infection segment has the highest revenue of US $97.83 billion and is expected to grow at CAGR of 11.46% by 2027 HIV Infection segment has highest cagr growth of 11.46%.

HIV Infection

HIV Infection segment was valued at US $76.64 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $203.47 billion by 2027. HIV Infection segment represented US $21.19 billion opportunity over 2019-2021 and estimated to create US $105.64 billion opportunity in 2027 over 2021.

Pneumonia

Pneumonia segment was valued at US $50.25 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $133.40 billion by 2027. Pneumonia segment represented US $13.89 billion opportunity over 2019-2021 and estimated to create US $69.26 billion opportunity in 2027 over 2021.

Respiratory Virus Infection

Respiratory Virus Infection segment was valued at US $34.01 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $90.28 billion by 2027. Respiratory Virus Infection segment represented US $9.40 billion opportunity over 2019-2021 and estimated to create US $46.87 billion opportunity in 2027 over 2021.

Sepsis

Sepsis segment was valued at US $18.93 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $50.25 billion by 2027. Sepsis segment represented US $5.23 billion opportunity over 2019-2021 and estimated to create US $26.09 billion opportunity in 2027 over 2021.

Tuberculosis

Tuberculosis segment was valued at US $9.27 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $24.62 billion by 2027. Tuberculosis segment represented US $2.56 billion opportunity over 2019-2021 and estimated to create US $12.78 billion opportunity in 2027 over 2021.

Other Indications

Other Indications segment was valued at US $5.62 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $14.93 billion by 2027. Other Indications segment represented US $1.55 billion opportunity over 2019-2021 and estimated to create US $7.75 billion opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, Hospital Pharmacy segment has the highest revenue of US $138.00 billion and is expected to grow at CAGR of 11.46% by 2027 Hospital Pharmacy segment has highest cagr growth of 11.46%.

Hospital Pharmacy

Hospital Pharmacy segment was valued at US $108.11 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $287.02 billion by 2027. Hospital Pharmacy segment represented US $29.89 billion opportunity over 2019-2021 and estimated to create US $149.01 billion opportunity in 2027 over 2021.

Retail Pharmacy

Retail Pharmacy segment was valued at US $61.35 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $162.87 billion by 2027. Retail Pharmacy segment represented US $16.96 billion opportunity over 2019-2021 and estimated to create US $84.56 billion opportunity in 2027 over 2021.

Other Distribution Channels

Other Distribution Channels segment was valued at US $25.26 billion in 2019 and is projected to grow at 11.46% CAGR over the forecast period to reach US $67.06 billion by 2027. Other Distribution Channels segment represented US $6.98 billion opportunity over 2019-2021 and estimated to create US $34.82 billion opportunity in 2027 over 2021.